Literature DB >> 9670411

Quality adjusted survival analysis with repeated quality of life measures.

P P Glasziou1, B F Cole, R D Gelber, J Hilden, R J Simes.   

Abstract

One way of examining trade-offs between quantity and quality of life (QOL) is to combine them into a single measure such as quality-adjusted life year (QALY). If censoring occurs, then estimation presents some difficulties. One approach, known as Q-TWiST, is to define a series of health states, use a 'partitioned' survival analysis to calculate the average time in each state, and then weight each state according to its quality of life to calculate QALYs. Such health-state models, however, are unhelpful when the transitions between health states are unclear or if they do not adequately reflect variations in quality of life. We therefore examine an alternative analysis to be used when repeated measures of quality of life are available from individual patients in a clinical trial. The method proceeds by separating quality of life and survival, that is, dQALY/dt = S(t)Q(t), where S(t) is the survival curve, estimated from the standard Kaplan-Meier method, and Q(t) is the quality of life function, derived from individual repeated measures of quality of life. We derive single health-state (QALY) and multiple health-state (Q-TWiST) models and illustrate the approach by comparing different durations of adjuvant chemotherapy for breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670411     DOI: 10.1002/(sici)1097-0258(19980615)17:11<1215::aid-sim844>3.0.co;2-y

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  18 in total

1.  Some remarks on failure-times, surrogate markers, degradation, wear, and the quality of life.

Authors:  D R Cox
Journal:  Lifetime Data Anal       Date:  1999-12       Impact factor: 1.588

2.  Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.

Authors:  Yifei Sun; Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2017-04-12       Impact factor: 5.033

Review 3.  Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.

Authors:  David Cella
Journal:  Oncologist       Date:  2011

4.  Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Authors:  Jaclyn Beca; Don Husereau; Kelvin K W Chan; Neil Hawkins; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

5.  Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.

Authors:  Adin-Cristian Andrei; Kathleen L Grady
Journal:  Qual Life Res       Date:  2014-01-07       Impact factor: 4.147

6.  Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.

Authors:  Michael Friedlander; Val Gebski; Emma Gibbs; Lucy Davies; Ralph Bloomfield; Felix Hilpert; Lari B Wenzel; Daniel Eek; Manuel Rodrigues; Andrew Clamp; Richard T Penson; Diane Provencher; Jacob Korach; Tomasz Huzarski; Laura Vidal; Vanda Salutari; Clare Scott; Maria Ornella Nicoletto; Kenji Tamura; David Espinoza; Florence Joly; Eric Pujade-Lauraine
Journal:  Lancet Oncol       Date:  2018-07-17       Impact factor: 41.316

7.  Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.

Authors:  Arthur S Zbrozek; Gary Hudes; Donna Levy; Andrew Strahs; Anna Berkenblit; Robert DeMarinis; Shreekant Parasuraman
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation.

Authors:  Bart S Ferket; Vinod H Thourani; Pierre Voisine; Samuel F Hohmann; Helena L Chang; Peter K Smith; Robert E Michler; Gorav Ailawadi; Louis P Perrault; Marissa A Miller; Karen O'Sullivan; Stephanie L Mick; Emilia Bagiella; Michael A Acker; Ellen Moquete; Judy W Hung; Jessica R Overbey; Anuradha Lala; Margaret Iraola; James S Gammie; Annetine C Gelijns; Patrick T O'Gara; Alan J Moskowitz
Journal:  J Thorac Cardiovasc Surg       Date:  2019-07-02       Impact factor: 5.209

Review 9.  Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data.

Authors:  Dennis A Revicki; David Feeny; Timothy L Hunt; Bernard F Cole
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

10.  Quality-adjusted life-years and helmet use among motorcyclists sustaining head injuries.

Authors:  Hsin-Yi Lee; Yeh-Hsin Chen; Wen-Ta Chiu; Jing-Shiang Hwang; Jung-Der Wang
Journal:  Am J Public Health       Date:  2010-01       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.